With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market.

GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033

Scope

Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC309PIDR-7M

1 Parkinson's Disease: Executive Summary

1.1 The PD market will grow to $7.9 billion
1.2 Novel symptomatic treatments will continue to shape the PD market
1.3 Opportunities and challenges for disease-modifying therapies entering the PD market
1.4 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming related reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
- 4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
- 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
4.5 Epidemiological forecast for PD (2023-33)
- 4.5.1 Diagnosed prevalent cases of PD
- 4.5.2 Age-specific diagnosed prevalent cases of PD
- 4.5.3 Sex-specific diagnosed prevalent cases of PD
- 4.5.4 Diagnosed prevalent cases of PD by HY clinical staging
- 4.5.5 Diagnosed prevalent cases of PD by type
- 4.5.6 Diagnosed prevalent cases of PD by inheritance type
- 4.5.7 Diagnosed prevalent cases of PD by motor complications
- 4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications - psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Formulations that reduce pill burden

8 R&D Strategies

8.1 Overview
- 8.1.1 Development of novel targets - targeting cell and gene therapies and a-synuclein
- 8.1.2 Innovative drug delivery systems
- 8.1.3 Secondary indications, post marketing requirements, and drug repurposing
8.2 Clinical trials design
- 8.2.1 Reliable biomarkers of disease progression
- 8.2.2 Genetic studies required to learn about genetic subtypes of PD

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment
- 10.2.1 Levodopa therapies
- 10.2.2 Dopamine agonists/combinations
- 10.2.3 Antiparkinsonian agents targeting motor complications
- 10.2.4 Assets targeting PD dementia
- 10.2.5 Neuroprotective and disease-modifying agents

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologists
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData